Already pursuing Baxalta in a hostile takeover battle, Shire announced the acquisition of US-based biotech company Dyax for $5.9bn upfront in cash (reflecting a c.35% premium to the company’s pre-announcement share price) and a contingent value right. Dyax currently sells Kalbitor, approved for the treatment of acute HAE in patients over 12 years. The main attraction for Shire, however, is its phase III ready HAE candidate, DX-2930, which carries fast-track, breakthrough therapy, and or
02 Dec 2015
A clever deal by buying Dyax
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A clever deal by buying Dyax
Shires Income PLC GBP (SHRS:LON) | 226 5.6 1.1% | Mkt Cap: 93.3m
- Published:
02 Dec 2015 -
Author:
Kamla Singh -
Pages:
2
Already pursuing Baxalta in a hostile takeover battle, Shire announced the acquisition of US-based biotech company Dyax for $5.9bn upfront in cash (reflecting a c.35% premium to the company’s pre-announcement share price) and a contingent value right. Dyax currently sells Kalbitor, approved for the treatment of acute HAE in patients over 12 years. The main attraction for Shire, however, is its phase III ready HAE candidate, DX-2930, which carries fast-track, breakthrough therapy, and or